The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move highlighting the biotech sector's persistence in navigating regulatory hurdles, Corcept Therapeutics announced it has resubmitted its New Drug Application (NDA) to the U.S. FDA for relacorilant. The resubmission follows a previous request from the regulator for additional data and information regarding the treatment for patients with Cushing’s syndrome. This step marks a critical milestone for the company as it seeks commercial approval for the cortisol-modulating medication.
This development occurs amid intense competition in the orphan drug market, where Corcept aims to strengthen its position against peers such as Recordati, which markets Signifor. Per market data, the potential approval of relacorilant could unlock significant growth avenues, given the limited therapeutic options currently available for Cushing’s syndrome. Analysts are closely monitoring the FDA's response to the updated data, as successful resubmissions typically bolster investment sentiment across the specialized pharmaceutical sector.
Sign in to access this content
Sign InOn the charts, CORT stood at $83.12 (close June 15, 2026), having reached a session high of $83.68. Investors should now watch for the FDA's acknowledgment of the filing, typically expected within 30 days of receipt. While the upcoming economic calendar shows no direct healthcare catalysts, broader market sentiment remains influenced by recent data such as the Michigan Consumer Sentiment, which printed at 48.9 on June 12.